DiaMedica Therapeutics Files 2025 Proxy Statement
Ticker: DMAC · Form: DEF 14A · Filed: Mar 28, 2025 · CIK: 1401040
| Field | Detail |
|---|---|
| Company | Diamedica Therapeutics Inc. (DMAC) |
| Form Type | DEF 14A |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: DMAC
TL;DR
DMAC proxy statement out - shareholders vote soon on exec pay & board.
AI Summary
DiaMedica Therapeutics Inc. filed its definitive proxy statement (DEF 14A) on March 28, 2025, for the fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related corporate governance matters. The company is headquartered in Minneapolis, MN, and its stock ticker is DMAC.
Why It Matters
This filing provides shareholders with essential information regarding upcoming votes, executive compensation, and board nominations, enabling informed participation in the company's governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing, which is standard for publicly traded companies and does not inherently indicate new risks.
Key Numbers
- 2024 — Fiscal Year End (The proxy statement covers the company's performance and governance for this period.)
Key Players & Entities
- DiaMedica Therapeutics Inc. (company) — Registrant
- 0001401040 (company) — Central Index Key
- MINNEAPOLIS (location) — Company Headquarters
- 20250328 (date) — Filing Date
- 20250515 (date) — Period of Report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxy votes from shareholders for their annual or special meetings, providing details on matters to be voted upon, such as director elections and executive compensation.
When was this DEF 14A filed by DiaMedica Therapeutics Inc.?
DiaMedica Therapeutics Inc. filed this DEF 14A on March 28, 2025.
What is the period of report for this filing?
The conformed period of report for this filing is May 15, 2025.
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. is headquartered in Minneapolis, MN.
What is the SIC code for DiaMedica Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for DiaMedica Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 28, 2025 regarding DiaMedica Therapeutics Inc. (DMAC).